TALIS BIOMEDICAL CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.14 USD | +1.56% |
|
+2.70% | +22.68% |
| Apr. 02 | North American Morning Briefing : Stocks Seen -2- | DJ |
| Mar. 28 | Talis Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 105.4 | 11.94 | 13.57 |
| Enterprise Value (EV) 1 | -113.2 | -84.67 | -43.5 |
| P/E ratio | -0.47 x | -0.11 x | -0.22 x |
| Yield | - | - | - |
| Capitalization / Revenue | 12.9 x | 2.48 x | 6.36 x |
| EV / Revenue | -13.8 x | -17.6 x | -20.4 x |
| EV / EBITDA | 0.59 x | 0.82 x | 0.69 x |
| EV / FCF | 1,802,939 x | 1,291,539 x | 1,197,111 x |
| FCF Yield | 0% | 0% | 0% |
| Price to Book | 0.45 x | 0.09 x | 0.2 x |
| Nbr of stocks (in thousands) | 1,753 | 1,785 | 1,821 |
| Reference price 2 | 60.15 | 6.685 | 7.450 |
| Announcement Date | 3/15/22 | 3/22/23 | 3/28/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 2.39 | 3.977 | 10.94 | 8.193 | 4.812 | 2.134 |
| EBITDA 1 | -20.78 | -25.97 | -90.42 | -190.2 | -102.7 | -63.28 |
| EBIT 1 | -21.43 | -26.7 | -91.18 | -191.8 | -111.5 | -64.05 |
| Operating Margin | -896.65% | -671.34% | -833.64% | -2,341.22% | -2,318.08% | -3,001.36% |
| Earnings before Tax (EBT) 1 | -21.34 | -27.47 | -91.13 | -192 | -113 | -62.01 |
| Net income 1 | -21.34 | -27.47 | -91.13 | -192 | -113 | -62.01 |
| Net margin | -892.76% | -690.82% | -833.15% | -2,343.9% | -2,348.55% | -2,905.67% |
| EPS 2 | -609.4 | -191.6 | -644.7 | -127.1 | -63.65 | -34.12 |
| Free Cash Flow | - | -14.97 | -97.19 | -62.76 | -65.56 | -36.33 |
| FCF margin | - | -376.34% | -888.53% | -766.01% | -1,362.41% | -1,702.65% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 1/6/21 | 1/6/21 | 3/30/21 | 3/15/22 | 3/22/23 | 3/28/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.218 | 0.858 | 3.187 | 0.572 | 0.796 | 0.257 | 1.218 | 0.581 |
| EBITDA | -38.18 | -27.58 | -32.6 | -26.29 | -22.86 | -24.55 | - | - |
| EBIT 1 | -38.42 | -28.52 | -32.97 | -27.27 | -26.79 | -28.11 | -19 | -16.39 |
| Operating Margin | -17,621.56% | -3,324.01% | -1,034.42% | -4,768.01% | -3,365.08% | -10,938.52% | -1,559.69% | -2,821.17% |
| Earnings before Tax (EBT) 1 | -38.42 | -28.65 | -33.05 | -27.01 | -26.02 | -26.93 | -17.83 | -15.03 |
| Net income 1 | -38.42 | -28.65 | -33.05 | -27.01 | -26.02 | -26.93 | -17.83 | -15.03 |
| Net margin | -17,622.94% | -3,339.63% | -1,037.06% | -4,722.2% | -3,268.97% | -10,478.21% | -1,463.96% | -2,587.61% |
| EPS 2 | -22.35 | -16.27 | -18.75 | -15.15 | -14.70 | -15.00 | -9.900 | -8.270 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 3/15/22 | 5/10/22 | 8/2/22 | 11/3/22 | 3/22/23 | 5/11/23 | 8/10/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 6.9 | 21.6 | 138 | 219 | 96.6 | 57.1 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -15 | -97.2 | -62.8 | -65.6 | -36.3 |
| ROE (net income / shareholders' equity) | - | -187% | -89.3% | -92.2% | -62.7% | -63.3% |
| ROA (Net income/ Total Assets) | - | -89.9% | -50.9% | -51.6% | -32% | -30.3% |
| Assets 1 | - | 30.55 | 179.2 | 371.8 | 352.7 | 204.4 |
| Book Value Per Share 2 | -1,485 | -150.0 | -766.0 | 133.0 | 70.90 | 37.90 |
| Cash Flow per Share 2 | 197.0 | 153.0 | 977.0 | 132.0 | 72.90 | 42.10 |
| Capex 1 | 0.53 | 0.58 | 8.2 | 2.87 | 1.62 | 0.49 |
| Capex / Sales | 22.3% | 14.53% | 74.98% | 34.98% | 33.56% | 22.77% |
| Announcement Date | 1/6/21 | 1/6/21 | 3/30/21 | 3/15/22 | 3/22/23 | 3/28/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +22.68% | 16.65M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- TLIS Stock
- Financials Talis Biomedical Corporation
